| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
Obsidian Therapeutics, Inc. Common Stock
$13.71
+0.38 (+2.89%)
Market Cap
846.60 M
EPS
-
P/E Ratio
-
Value Trade
916.06 K
6.61 %
Week
-19.35 %
1 Month
-59.68 %
3 Month
-59.68 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
32.10 K
52 Week Range
-
% held by Insiders
12.4 %
% held by Institutions
15.01 %
Enterprise Value
848.14 M
Total Shares
61.73 M
Short %
0.47 %
Float Shares
54.11 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Obsidian Therapeutics, Inc. Common Stock
7Total events
3Upcoming
4Tier-1 (high impact)
2026 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Enrollment Complete
Subscribe to view catalyst details
Event history 2
TBD
▲First Patient Dosedamsoki-celTrial
Subscribe to view catalyst details
TBD
▲FDA Feedback Receivedamsoki-celFDA Meeting
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OBX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OBX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-OBX
Oct 2, 2026▲ +2.9%today
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Obsidian Therapeutics has announced a poster presentation of updated data on amsoki-cel for patients with immune-checkpoint inhibitor-resistant advanced melanoma. This data is derived from both a Phase 1 single-center first-in-human study and a Phase 1/2 multicenter study. The presentation will take place at the SITC 2026 Annual Meeting.
Read more →-OBX
Aug 5, 2026▼ -16.1%on this news
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
Obsidian Therapeutics has successfully enrolled the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study. This study evaluates amsoki-cel, an engineered tumor-infiltrating lymphocyte therapy, for treating advanced melanoma. The enrollment marks a crucial step towards potential regulatory approval for this innovative treatment.
Read more →-OBX
Aug 3, 2026Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
Obsidian Therapeutics has completed its merger with Galera Therapeutics and raised $350 million through a private placement. The combined company will focus on advancing its engineered TIL cell therapies, particularly OBX-115, which is in clinical trials for solid tumors. The funding is expected to support operations through key clinical milestones until the second half of 2028.
Read more →-OBX
May 21, 2026Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
Obsidian Therapeutics announced promising Phase 2 results for OBX-115, an engineered TIL cell therapy for advanced melanoma. The therapy demonstrated a 67% objective response rate, including two complete responses, with a favorable safety profile. The results will be presented at the 2026 ASCO Annual Meeting, highlighting OBX-115's potential as a viable treatment option for patients with difficult-to-treat melanoma.
Read more →-OBX
Apr 21, 2026Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
Obsidian Therapeutics will present Phase 2 clinical data for OBX-115, an engineered TIL cell therapy, at the 2026 ASCO Annual Meeting. The study focuses on patients with advanced melanoma who have not responded to immune checkpoint inhibitors. The presentation is scheduled for June 1, 2026, and aims to highlight the therapy's potential benefits.
Read more →-OBX
Jan 12, 2026Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer
Obsidian Therapeutics has appointed Julie Feder as Chief Financial Officer. With over 20 years of experience in strategic finance, Feder's expertise is expected to support the company's clinical development of OBX-115, an engineered TIL cell therapy. The appointment comes at a crucial time as the company progresses towards registration-enabling trials.
Read more →-OBX
Jun 2, 2025Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Obsidian Therapeutics presented positive Phase 1 clinical data for OBX-115 at the 2025 ASCO Annual Meeting. The study involved 11 patients with advanced melanoma who were resistant to immune checkpoint inhibitors. The novel therapy, which utilizes engineered TIL cells, achieved an overall response rate of 67%.
Read more →-OBX
Apr 28, 2025Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting
Obsidian Therapeutics announced the presentation of preclinical data from its cytoDRiVE platform at the ASGCT Annual Meeting 2025. The data showcases novel applications for regulating therapeutic proteins, including a new approach using artificial transcription factors. The lead program, OBX-115, aims to treat patients with advanced melanoma by leveraging pharmacologically regulatable IL15.
Read more →-OBX
Apr 25, 2025Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
Obsidian Therapeutics announced the presentation of three abstracts at the AACR Annual Meeting 2025, showcasing advancements in their engineered cell and gene therapies. Highlights include updates on the Agni-01 trial and preclinical data from the cytoDRiVE platform, which enhances IL12 expression for improved tumor control. The findings suggest potential benefits for patients with advanced solid tumors.
Read more →-OBX
Apr 23, 2025Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Melanoma in Oral Presentation at the 2025 ASCO Annual Meeting
Obsidian Therapeutics announced two presentations at the 2025 ASCO Annual Meeting, including an oral presentation of Phase 1 results from the Agni-01 study of OBX-115, an engineered TIL cell therapy for patients with ICI-resistant advanced melanoma. The presentations will take place from June 1-3, 2025, in Chicago.
Read more →Competitive Position
How OBX ranks across every disease it competes inCompetitive Position is a premium feature
See how OBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial